Kalit so‘zlar
Abstrak
Mazkur maqolada arterial gipertenziyani davolashning zamonaviy usullari va ularning klinik samaradorligi tahlil qilinadi. Tadqiqotda farmakologik va nofarmakologik davolash yondashuvlari, antihipertenziv preparatlarning asosiy guruhlari, kombinatsiyalangan terapiya hamda arterial qon bosimini muntazam monitoring qilish masalalari yoritilgan.
Zamonaviy ilmiy tadqiqotlar asosida individual davolash strategiyasining ahamiyati, bemorning terapiyaga rioya qilishi va turmush tarzini o‘zgartirishning davolash natijalariga ta’siri ko‘rib chiqiladi. Tadqiqot natijalari arterial gipertenziyani kompleks va individual yondashuv asosida davolash qon bosimini samarali nazorat qilish hamda yurak-qon tomir asoratlari xavfini kamaytirishda muhim ekanligini ko‘rsatadi.
References
Coca A., Whelton S. P., Camafort M., López-López J. P., Yang E. Single-pill combination for treatment of hypertension: Just a matter of practicality or is there a real clinical benefit? // European Journal of Internal Medicine. – 2024. – Vol. 126. – P. 16–25.
Soh M. S., Won K. H., Kim J. J. et al. Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment // Scientific Reports. – 2024. – Vol. 14. – Article 22940. –
Zhang K., Song Q., Bai J. et al. Association of intensive blood pressure management with cardiovascular outcomes in patients using multiple classes of antihypertensive medications: a post-hoc analysis of the STEP Trial // Hypertension Research. – 2024. – Vol. 47. – P. 1779–1788.
Heaton J., Johal A., Alshami A. et al. Effect of combination antihypertensive pills on blood pressure control // Journal of the American Heart Association. – 2024. – Vol. 13, № 23. – Article e036046.
Li Y. H., Lin H. W., Gottwald-Hostalek U. et al. Clinical outcome in hypertensive patients treated with amlodipine plus bisoprolol or plus valsartan // Current Medical Research and Opinion. – 2024. – Vol. 40, № 8. – P. 1267–1276. –
Irbesartan/Amlodipine combination therapy in patients with essential hypertension whose blood pressure was not controlled by irbesartan monotherapy // Clinical Therapeutics. – 2024. – Vol. 46, № 6. – P. 481–489.